Skip to main content Skip to main navigation menu Skip to site footer
Global Cardiology

eISSN 2975-2728

  • About the Journal
  • Editorial Board
  • Publication Ethics
  • Current
  • Archives
  • || New papers ||
  • Special Issues
    • Overview
  • Copyright & Licensing
  • Register
  • Login
  • Search
  • Contacts
  • News

Editor-in-Chief: Andrew J.S. Coats, Australia

Submit
an article
  1. Home /
  2. Search

Search

Advanced filters
Published After
Published Before

Search Results

##search.searchResults.foundPlural##
  • The effect of sauna on cardiac and skeletal muscle function in patients with HFpEF (SAUNA-HFpEF): rationale and design

    Tarek Bekfani, Kris G. Vargas, Flor Gomez, Alexander Schmeisser, Ruediger C. Braun-Dullaeus
    2025-06-30
    https://doi.org/10.4081/cardio.2025.67
    2600
    PDF: 516
    HTML: 127
  • Treatment pathways in patients with heart failure with preserved ejection fraction and obesity: perspectives from cardiology specialists and patients

    Javed Butler, Sanjiv J. Shah, Melissa Magwire, Carlos Campos, Muhammad Shariq Usman, Anthony Hoovler, Anup Sabharwal, Barry A. Borlaug
    2024-06-28
    https://doi.org/10.4081/cardio.2024.38
    2118
    PDF: 574
    SUPPLEMENTARY MATERIAL: 318
    GRAPHICAL ABSTRACT: 281
    HTML: 44
  • Effect of metformin and empagliflozin on myocardial function in insulin-resistant patients with heart failure: rationale and design of the METRIS-HF-DZHK18 Trial

    Wolfram Doehner, Tim Friede, Frank Edelmann, Ulf Landmesser, Sebastian Winkler, Burkert Pieske, Fabian Knebel, Sebastian Kelle, Diethelm Tschöpe, Antje Meyer, Nadja Jauert, Marius Placzek, Jeanette Schulz-Menger, Stephan von Haehling, Stefan D. Anker
    2025-12-31
    https://doi.org/10.4081/cardio.2025.89
    261
    PDF: 77
    Appendix: 27
    HTML: 9
  • Sex differences in clinical characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction

    Christian Basile, Stefan D. Anker, Gianluigi Savarese
    2025-07-16
    https://doi.org/10.4081/cardio.2025.76
    863
    PDF: 230
    Supplementary: 167
    Appendix: 121
    HTML: 50
  • Iron deficiency in heart failure with preserved ejection fraction: rationale and design of the FAIR-HFpEF trial

    Stephan von Haehling, Wolfram Doehner, Ruben Evertz, Tania Garfias-Veitl, Monika Diek, Mahir Karakas, Ralf Birkemeyer, Gerasimos Fillippatos, Piotr Ponikowski, Michael Böhm, Tim Friede, Stefan D. Anker
    2023-12-27
    https://doi.org/10.4081/cardio.2023.15
    2696
    pdf: 691
    HTML: 46
  • The effect of SGLT2 inhibitors on health status in patients with heart failure: a systematic review and meta-analysis

    Muhammad Shariq Usman, Arsalan Hamid, Shurjeel Uddin Qazi, Mikhail N. Kosiborod, Deepak L. Bhatt, Muhammad Shahzeb Khan, Muthiah Vaduganathan, Javed Butler
    2024-06-28
    https://doi.org/10.4081/cardio.2024.35
    2843
    PDF: 707
    Conflict of interest: 334
    SUPPLEMENTARY MATERIAL: 283
    HTML: 81
  • The association of iron deficiency with right ventricular dysfunction in Africans with heart failure

    Adeseye A. Akintunde, Sope T. Orugun
    2024-12-30
    https://doi.org/10.4081/cardio.2024.53
    2501
    PDF: 423
    Appendix B: 464
    Appendix A: 332
    HTML: 6
  • Exercise capacity, iron deficiency and depressive symptoms in patients with asymptomatic chronic systolic heart failure

    Sven Christopher Aland, Christoph Gertler, Hannah Leonie Bräunig, Timo Schröder, Frank Edelmann, Rolf Wachter, Christoph Herrmann-Lingen, Gerd Hasenfuß, Anja Sandek
    2024-06-28
    https://doi.org/10.4081/cardio.2024.39
    1662
    PDF: 513
    HTML: 10
  • Using multiple primary endpoints in clinical trials with a focus on heart failure

    Stefan D. Anker, Javed Butler, Khawaja M. Talha, Tim Friede
    2024-06-28
    https://doi.org/10.4081/cardio.2024.33
    5835
    PDF: 797
    HTML: 279
  • SGLT2 inhibitors and risk reduction for mortality in high-risk patients: a meta-analysis of randomized controlled trials

    Tariq Jamal Siddiqi, Javed Butler, Andrew J.S. Coats, Subodh Verma, Tim Friede, Gerasimos Filippatos, Stefan D. Anker
    2023-11-23
    https://doi.org/10.4081/cardio.2023.2
    1285
    pdf: 293
    Supplementary Material: 48
    HTML: 156
  • Aldosterone synthase inhibitors in cardio-renal diseases: a state-of-the-art review

    Muhammad Hamza Dawood, Muhammad Shahzeb Khan, Ahmed Mustafa Rashid, Wilhelm Haverkamp
    2025-12-31
    https://doi.org/10.4081/cardio.2025.91
    405
    PDF: 129
    HTML: 18
  • Beyond trial neutrality: treatment discontinuation and the hidden signal in SPIRIT-HF trial

    Viana Copeland, Andrew J.S. Coats
    2026-03-31
    https://doi.org/10.4081/cardio.2026.100
    19
    PDF: 21
1 - 12 of 12 items

authors

FOR AUTHORS
  • SUBMIT YOUR PAPER
  • Guide for Authors
  • Benefits for Authors
  • How to write a Scientific paper
  • How to write a Review article
  • Article Processing Charge

reviewers

FOR REVIEWERS
  • How to Review

indexing

INDEXING
  • DOAJ
  • Google Scholar
  • OpenAlex
  • Scilit
  • Analytics

iCARDIO

May 1 marked the release of the #iCARDIO Guidelines on Heart Failure, now live in Global Cardiology. This global-first effort brings flexible, practical guidance to frontline providers managing #heartfailure in any setting. www.globalcardiology.info/site/article... #GlobalHealth #cardiosky

[image or embed]

— iCardio (@icardio.bsky.social) May 13, 2025 at 8:26

Keywords

Vol. 4 No. 1 (2026)
Draft Document for Public Consultation: iCARDIO Alliance Global Implementation Guidelines on Ischemic Heart Disease Management 2026

Ischemic heart disease (IHD) remains the leading cause of morbidity and mortality worldwide.  Coronary artery disease (CAD) encompasses any pathological process capable of compromising myocardial perfusion and although numerous etiologies exist, including vasculitis, spontaneous coronary artery dissection, and coronary embolism, the majority of CAD is attributable to coronary atherosclerosis, which constitutes the focus of this document. For practical purposes, CAD is considered present when any degree of atherosclerotic involvement...

Writing Task Force | iCARDIO-Alliance
5 February 2026
Vol. 4 No. 1 (2026)
MASLD and cardiovascular disease: a state-of-the-art review

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly nonalcoholic fatty liver disease, is the most prevalent chronic liver disease worldwide, affecting more than 30% of adults and up to 70–90% of individuals with obesity or type 2 diabetes mellitus. Cardiovascular disease (CVD) represents the leading cause of mortality in this population. MASLD is increasingly recognized as an independent cardiovascular risk factor beyond traditional metabolic comorbidities. This narrative review summarizes epidemiologic,...

Aimen Shafiq et al.
10 April 2026
Global Cardiology

is an Open Access, peer-reviewed journal published online by PAGEPress®, Pavia, Italy.
[Website continuously updated]

eISSN: 2975-2728

Info

  • About
  • Editorial Board
  • News

Info Submission

  • Submission
  • Guidelines For Authors
Themes by Openjournaltheme.com

© PAGEPress 2008-2026    •    PAGEPress® is a registered trademark property of PAGEPress srl, Italy    •    VAT: IT02125780185    •    Privacy